SPTX outlines Glyph platform oral-therapy progress for depression, anxiety
SPTX says its Glyph platform targets oral bioavailability and liver-toxicity challenges. Lead programs GlyphAllo and GlyphAgo target depression and anxiety, with registration-enabling trials planned.